Core Insights - IREN Limited reported record monthly revenue of $86 million and hardware profits of $66 million in July 2025, driven by strong Bitcoin mining economics and demand for AI Cloud services [7][5][11] Bitcoin Mining Performance - Average operating hashrate increased to 45.4 EH/s in July from 41.1 EH/s in June [4] - Total Bitcoin mined rose to 728 BTC in July, up from 620 BTC in June [4] - Revenue per Bitcoin mined increased to $114,891 from $105,730 [4] - Net electricity cost per Bitcoin mined was $27,976, compared to $26,259 in June [4] - Total revenue from Bitcoin mining reached $83.6 million, up from $65.5 million in June [4] - Hardware profit from Bitcoin mining was $63.3 million with a profit margin of 76%, slightly up from 75% in June [4] AI Cloud Services - Revenue from AI Cloud services was $2.3 million, a slight increase from $2.2 million in June [6] - Hardware profit for AI Cloud services was $2.3 million with a consistent profit margin of 98% [6] - The company expanded its AI Cloud capabilities with the addition of 2,400 NVIDIA B200/B300 GPUs and completed the initial shipment of B200 GPUs [5][11] Infrastructure and Growth Initiatives - The 50MW Horizon 1 liquid-cooled AI data center is on track for completion in Q4 2025 [5] - Mackenzie fiber upgrade has been completed, enhancing network redundancy and supporting AI Cloud growth [5][11] - Civil and electrical works for the 1,400MW Sweetwater 1 project are ongoing [5] Management Commentary - Management highlighted the adaptability of their infrastructure to run ASICs and GPUs side-by-side, capturing market opportunities [8] - The company is experiencing accelerating interest in newly procured Blackwell GPUs, with significant contracts already in place [8][11]

Company Overview - Stack Capital Group Inc. reported its financial results for the quarter ended June 30, 2025, with all amounts in Canadian Dollars [1] - The Company aims to invest in growth-to-late-stage private businesses, providing shareholders with exposure to a diversified private investment portfolio [7] Financial Performance - As of June 30, 2025, the Book Value of the Company was $157.6 million, and the Book Value per Share was $14.34, an increase from $12.06 as of March 31, 2025 [3][5] - The Company marked up its investment in CoreWeave by US$25.7 million, reflecting a closing price of US$163.06 [5] - An additional US$3 million was invested in SpaceX during Q2-2025, with SpaceX's valuation increasing from US$350 billion to US$400 billion post-quarter [5] Investment Portfolio - The breakdown of Book Value per Share as of June 30, 2025, includes significant investments in various companies: - CoreWeave, Inc. (AI hyper-scaler): $4.25 - SpaceX: $2.47 - Locus Robotics, Inc. (autonomous robots): $1.26 - Canva, Inc. (graphic design): $1.23 - Omio, Inc. (travel & leisure): $1.05 - Hopper, Inc. (travel & leisure): $1.03 - Newfront Insurance, Inc. (insurance & benefits): $1.02 - Prove Identity, Inc. (cyber-security): $0.98 - Bolt Financial, Inc. (e-commerce): $0.48 - Shield AI, Inc. (military defense): $0.39 - Varo Money, Inc. (neo-banking): $0.13 - Cash: $0.50 - Net other assets: $(0.45) [4] Market Environment - The CEO of Stack Capital noted a robust IPO environment and strong momentum in private markets, particularly among disruptive companies in AI, LLMs, and robotics [3] - The Company remains focused on backing category-leading businesses that can deliver long-term value for shareholders [3]

Core Viewpoint - FOXO Technologies Inc. has executed a non-binding acquisition agreement to acquire an assisted living and memory care facility in South Florida for an expected purchase price of $22 million [1][2]. Group 1: Acquisition Details - The acquisition includes the land and buildings of a facility with 87 licensed units for assisted living and memory care services [2]. - The purchase price will consist of $5 million in non-convertible preferred stock, with a portion of the price being milestone-based [2]. - Completion of the acquisition is contingent upon definitive agreements and various closing conditions, including satisfactory due diligence and financing [2]. Group 2: Strategic Expansion - The CEO of FOXO stated that this agreement aligns with the company's strategy to expand its healthcare services by adding assisted living facilities [3]. - The company is confident in closing on additional acquisitions that could add over 350 units for assisted living and memory care services [3]. - FOXO is also in advanced stages of confirming a definitive agreement for the acquisition of Vector Biosource, Inc. [3]. Group 3: Future Outlook - FOXO is actively exploring and negotiating further opportunities in the assisted living and behavioral health sector, with imminent expansion plans for its Myrtle Recovery Centers, Inc. business [4]. - The company anticipates filing its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, by August 14, 2025, expecting to show continued improvement in net revenues, profitability, and stockholders' equity [4]. Group 4: Company Overview - FOXO Technologies Inc. operates three subsidiaries: Rennova Community Health, Inc., Myrtle Recovery Centers, Inc., and FOXO Labs, Inc., focusing on healthcare and biotechnology [5][6].

Core Viewpoint - Clearway Energy, Inc. has announced a $100 million At-The-Market equity offering program to raise capital for general corporate purposes, including debt repayment, working capital, and investments [1][3]. Group 1: Equity Offering Details - The company will offer shares of its Class C common stock through an Equity Distribution Agreement with major financial institutions including Morgan Stanley, BofA Securities, Citigroup, J.P. Morgan, and Wells Fargo Securities [1]. - The shares will be sold at market prices on the New York Stock Exchange, with an aggregate sales price of up to $100 million [1][4]. - The offering is made under a prospectus supplement dated August 6, 2025, linked to the company's shelf registration statement effective since August 8, 2023 [2]. Group 2: Use of Proceeds - The net proceeds from the equity offering will be utilized for general corporate purposes, which may include repayment or refinancing of debt, funding working capital, capital expenditures, and potential acquisitions [3]. - The company may also invest any immediate surplus funds in marketable securities and short-term investments [3]. Group 3: Company Overview - Clearway Energy, Inc. is a significant owner of clean energy generation assets in the U.S., with a portfolio of approximately 12 GW of gross capacity across 27 states [5]. - The portfolio includes around 9.2 GW of wind, solar, and battery energy storage systems, and approximately 2.8 GW of dispatchable combustion-based power generation assets [5]. - The company aims to provide stable and growing dividend income to its investors through its diversified and primarily contracted portfolio [5].

Core Insights - Helix Acquisition Corp. II has retained approximately $120 million in its trust account, net of redemptions, representing over 60% of the cash held in trust [1] - The transaction is expected to raise approximately $382 million in gross proceeds, including $120 million from Helix's trust account and about $261 million from a private placement transaction [2] - Helix and TheRas, Inc. (BridgeBio Oncology Therapeutics) plan to expedite the closing of their business combination, pending the satisfaction or waiver of closing conditions [3] Company Overview - Helix Acquisition Corp. II is a special purpose acquisition company (SPAC) formed to effect a merger or similar business combination, having raised $184 million in its initial public offering on February 9, 2024 [4] - TheRas, Inc. (BridgeBio Oncology Therapeutics) is a clinical-stage biopharmaceutical company focused on developing novel small molecule therapeutics targeting RAS and PI3Kα malignancies, initially formed as a subsidiary of BridgeBio Pharma, Inc. [5] Financial Highlights - The combined company will have access to gross proceeds of approximately $120 million from the trust account and approximately $261 million from PIPE financing at the closing [7] - The transaction reflects the lowest redemption rate for a biotech de-SPAC transaction since 2022 [7]

WATERTOWN, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint will participate in a fireside chat at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on Thursday, August 13, 2025 at 10:00 a.m. ET. A live webcast and subsequent ...

Q2 total revenue of $10.7M includes previously-deferred revenue following reacquisition of Greater China rights to imdusiran Dr. Roger Sawhney joins the Arbutus Board of Directors following resignation of Anuj Hasija Dr. Harry Janssen joins the Arbutus Scientific Advisory Board Strong financial position with cash, cash equivalents and marketable securities of $98.1M WARMINSTER, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage ...

Core Insights - Lexicon Pharmaceuticals is making significant progress in its R&D strategy, with ongoing partnership discussions for pilavapadin and IND-enabling studies for LX9851 on track for completion in 2025 [3][4][8] - The company reported a substantial increase in total revenues for Q2 2025, reaching $28.9 million, compared to $1.6 million in Q2 2024, primarily driven by licensing revenue from Novo Nordisk [11][21] - Lexicon's net income for Q2 2025 was $3.3 million, a notable improvement from a net loss of $53.4 million in the same period last year [14][21] Partnership and Product Development - Partnership discussions for pilavapadin are ongoing, with full Phase 2 data expected to be presented at an upcoming medical meeting [3][8] - LX9851, a novel oral candidate for obesity, is in preclinical development, with an exclusive licensing agreement with Novo Nordisk that includes an upfront payment of $45 million and potential milestone payments up to $1 billion [8][11] - The SONATA Phase 3 study for sotagliflozin in hypertrophic cardiomyopathy (HCM) is progressing well, with over 100 sites initiated across 20 countries [3][16] Financial Performance - Total revenues for Q2 2025 were $28.9 million, consisting of $27.5 million in licensing revenue and $1.3 million from INPEFA® sales [11][21] - Research and development expenses decreased to $15.7 million in Q2 2025 from $17.6 million in Q2 2024, reflecting optimized resource allocation [12][21] - Selling, general, and administrative expenses significantly decreased to $9.4 million in Q2 2025 from $39.2 million in Q2 2024 due to strategic repositioning [13][21] Cash Position and Investments - As of June 30, 2025, Lexicon had $139 million in cash and investments, down from $238 million at the end of 2024, primarily due to severance payments related to strategic changes [15][21] - The company also reported $29 million in restricted cash as of the same date [15][21] Pipeline and Future Outlook - Lexicon is focused on advancing its pipeline, with sotagliflozin being commercially available in the U.S. for heart failure as INPEFA® [7][19] - The company is also preparing for regulatory filings for sotagliflozin in various international markets, with submissions already made in the UAE and Saudi Arabia [16][19]

Company Overview - Zevra Therapeutics, Inc. is a commercial-stage company focused on developing therapies for rare diseases with limited or no treatment options, aiming to provide life-changing therapeutics to affected individuals [3]. Upcoming Events - Members of Zevra's executive leadership team will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference in Boston, MA, on August 13, 2025, at 1:00 p.m. ET [1]. - Management will also be available for one-on-one meetings with registered conference attendees [2]. Investor Relations - A live webcast of the fireside chat will be accessible via the "Events & Presentations" section on Zevra's Investor Relations website [2].

Core Business Performance - Holley Performance Brands reported a core business net sales growth of 3.9% in the second quarter of 2025 compared to the same period in 2024, marking the second consecutive quarter of growth [9][8] - The company's net sales decreased by 1.7% to $166.7 million from $169.5 million year-over-year [8][19] - New product launches contributed approximately $8 million in revenue during the second quarter [5] Financial Highlights - Net income for the second quarter was $10.9 million, or $0.09 per diluted share, down from $17.1 million, or $0.14 per diluted share, in the prior year [8][20] - Adjusted EBITDA for the quarter was $36.4 million, compared to $38.3 million in the previous year [8] - Free cash flow reached $35.7 million, the highest level in the company's history, compared to $24.4 million last year [8][15] Strategic Initiatives - The company successfully mitigated tariff impacts through strategic sourcing and pricing actions, leading to increased guidance visibility [6][15] - Holley has refined its full-year guidance for 2025, projecting net sales between $580 million and $595 million, reflecting a year-over-year growth of 0.8% to 3.4% [10] - The company achieved approximately 6.5% growth in its B2B channel and over 8.6% growth in direct-to-consumer orders during the second quarter [15] Operational Efficiency - Net cash provided by operating activities was $40.5 million, significantly higher than $25.7 million in the prior year [8][25] - The company reported a gross profit of $69.6 million, a slight decrease from $70.3 million year-over-year, but an increase in gross profit margin was noted [19] - Operating income for the second quarter was $27.5 million, compared to $27.9 million in the previous year [19]